SCHEDULE: Precision BioSciences: Empery Asset Management Reports Stake

Empery Asset Management, LP and Ryan M. Lane have filed a Schedule 13G, reporting beneficial ownership of 4.99% of Precision BioSciences, Inc. common stock.

Summary

• Empery Asset Management, LP and Ryan M. Lane have filed an amendment to their Schedule 13G, indicating their beneficial ownership of Precision BioSciences, Inc. common stock.
• The filing reports a total of 1,314,393 shares beneficially owned, which represents 4.99% of the class of securities.
• This ownership includes 538,300 shares of common stock issuable upon the exercise of warrants.
• The reporting persons cannot exercise all warrants due to a 'Blocker' provision, which limits beneficial ownership to 4.99% of outstanding shares.
• The filing is an amendment, indicating a change or update to previously reported holdings.
• The reporting date for this filing is June 30, 2026.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it represents a standard disclosure of a significant but passive investment stake, without immediate positive or negative implications for the company's operations or valuation.

Positives

• Reporting persons have acquired a significant stake, approaching the 5% threshold, which could signal confidence in the company's future.
• The inclusion of exercisable warrants suggests potential for increased ownership and future capital infusion into the company upon exercise.

Negatives

• The 'Blocker' provision limits the full exercise of warrants, capping the ownership stake at 4.99% and preventing a larger potential investment.
• The filing is an amendment, which could imply a change in strategy or a response to market conditions rather than a new, proactive investment.

Risks

• The 'Blocker' provision limits the reporting persons' ability to exercise all warrants, potentially restricting their influence or investment upside.
• The filing does not provide specific reasons for the acquisition or any strategic intentions beyond the reported ownership percentage.

Future Outlook

The filing does not contain specific forward-looking statements or guidance from the company. It solely reports the beneficial ownership stake of Empery Asset Management, LP and Ryan M. Lane.

Industry Context

StockSavvy.ai notes that Schedule 13G filings typically indicate passive investment stakes by institutional investors. The 4.99% ownership level is common for investors seeking to avoid triggering stricter reporting requirements associated with active control or significant influence.

Stakeholder Impact

• Shareholders: The filing indicates a substantial investor has taken a significant stake, which could be perceived positively if the investor is seen as value-oriented, or neutrally if it's a standard passive holding.
• Company Management: May need to engage with or monitor the intentions of this significant shareholder, although the passive nature of the filing suggests no immediate pressure for strategic changes.

Next Steps

• The reporting persons will continue to monitor their beneficial ownership percentage in Precision BioSciences, Inc.
• Further filings may be required if ownership levels change significantly or if investment intent shifts from passive to active.

Key Dates

Keywords

Precision BioSciences, Schedule 13G, Empery Asset Management, Ryan M. Lane, Beneficial Ownership, Warrants, Investment Management, SEC Filing